Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

BMC Psychiatry

Volumn 5, Issue , 2005, Pages

  Ascher Svanum, Haya ^a   Stensland, Michael D ^a   Zhao, Zhongyun ^a   Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NEGATIVE SYNDROME; POSITIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SEX DIFFERENCE; SHORT FORM 36; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; OBESITY; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; OBESITY; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 12944295044     PISSN: 1471244X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-244X-5-3     Document Type: Article

References (52)

1. American Psychiatric Association: Practice Guidelines for the Treatment of Patients with Schizophrenia, Second Edition. Am J Psychiatry 2004, 161:1-56.
2. Bagnall A-M, Jones L, Ginnelly L, Lewis R, Glanville J, Gillbody S, Davis L, Torgerson D, Kleijnen J: A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assesss 2003, 7(13).
3. Lee IM, Paffenbarger RS Jr: Changes in body weight and longevity. JAMA 1992, 268, 2045-2049.
4. Taylor DM, McAskill R: Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000, 101 416-432.
5. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999, 156 1686-1696.
6. Umbricht DS, Pollack S, Kane JM: Clozapine and weight gain. J Clin Psychiatry1994, Suppl B:157-160.
7. Hummer M, Kemmler G, Kurtz M, Kurtzthaler I, Oberbauer H, Fleischhacker WW: Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995, 5: 437-440.
8. Bustillo JR, Buchanan RW, Isirh D, Breier A: Differential effect of clozapine weight: a controlled study. Am J Psychiatry 1996, 153:817-819.
9. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A: Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002, 159:1058-1060.
10. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M: Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992, 149:68-72.
11. Lamberti JS, Bellnier T, Schwarzkopf SB: Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992, 149:686-690.
12. Gupta S, Droney T, Al-Samarrai S, Keller P, Fran B, 1999. Olanzapine: Weight gain and therapeutic efficacy. J Clin Psychopharmacol 1999, 19:273-274.
13. Bai YM, Lin CC, Chen JY, Lin CY: Weight gain among patients on clozapine. Psychiatr Serv 1999, 50:704-705.
14. Ritter LM, Meador-Woodruff JH, Dalack GW:Weight gain and response to olanzapine treatment in schizophrenia [abstract]. Biol Psychiatry 2000, 47:48S.
15. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gillmore JA, Tollefson GD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001, 62:231-238.
16. Meltzer HY, Perry E, Jayathilake K: Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2002, 59: 19-27.
17. Czobor P, Volavka J, Sheitman B, Lindenmaer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA: Antipsychotic-induced weight gain and therapeutic response: A differential association. J Clin Psychopharm 2002, 22:244-251.
18. Garyfallos G, Dimelis D, Kounaiakis P, Sidiropoulos N, Karastergiou A, Lavrentiadis G, Giouzepas J, Fokas K: Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. European Psychiatry 2003, 18:320-321.
19. Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH: Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 2003, 64:316-320.
20. Planansky K, Heilizer F: Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin Exp Psychopathol 1959, 20:53-57.
21. Klett CJ, Caffey EM: Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry 1960, 2: 02-108.
22. Singh MM, De Dios LV, Klein NS: Weight as a correlate of clinical response to psychotropic drugs. Psychosomatics 1970, 11:562-570.
23. Sarlio-Lahteenkorva S: Weight loss and quality of life among obese people. Social Indicators Research 2001, 54: 29-354.
24. Rumpel C, Ingram DD, Harris TB, Madans J: The association between weight change and psychological well being in women. Int J Obes 1994, 18:179-183.
25. Le Pen C, Levy E, Loos F, Banzet MN, Basdevant A: "Specific" scale compared with "generic" scale: a double measurement of the quality of life in a French community sample of obese subjects. J Epidemiol Community Health 1998, 52:445-450.
26. Stafford M, Hemingway H, Marmot M: Current obesity, steady weight change and weight fluctuation as predictors of physical functioning in middle aged office workers: the Whitehall II Study. Int J Obes Relat Metab Disord 1998, 22:23-31.
27. Emslie C, Hunt K, Macintyre S: Perceptions of body image among working men and women. J Epidemiol Community Health 2001, 55:406-407.
28. Neumark-Sztainer D, Sherwood NE, French SA, Jeffery RW: Weight control behaviors among adult men and women: cause for concern? Obes Res 1999, 7:179-188.
29. Kawachi I: Physical and psychological consequences of weight gain. J Clin Psychiatry 1999, Suppl 21:5-9.
30. Blin O, Micallef J: Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001, Suppl 7:11-21.
31. Kurzthaler I, Fleischhacker WW: The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001, Suppl 7:32-37.
32. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997, 154:457-465.
33. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962, 10:799-812.
34. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
35. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134: 82-389.
36. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
37. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB: Gender differences in chronic major and double depression. J Affect Disord 2000, 60:1-11.
38. Siris SG, Addington D, Azorin JM, Falloon IR, Gerlach J, Hirsch SR: Depression in schizophrenia: recognition and management in the USA. Schizophr Res 2001, 47:185-197.
39. Birchwood M, Mason R, MacMillan F, Healy J: Depression, demoralization and control over psychotic illness: a comparison of depressed and nondepressed patients with a chronic psychosis. Pschol Med 1993, 23:387-395.
40. Tollefson GD, Andersen SW, Tran PV: The course of depressive symptoms in predicting relapse in schizophrenia: a double blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999, 46:365-373.
41. Keck PE, Starkowski SM, McElroy SL: The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry2000, 61:4-9.
42. Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003, 54:565-567.
43. Fetter JC: Weight gain and quality of life among patients taking antipsychotics. Psychiatr Serv2003, 54:1041.
44. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J,. et Mintz J, Marder SR: Novel antipsychotics: comparison of weight gains liabilities. J Clin Psychiatry 1999, 60: 58-363.
45. Fakhoury WK, Wright D, Wallace M: Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001, 16:153-162.
46. Krypsin-Exner W: Beitrage zum verlauf des kopergewichtes bei psychosen. Wiener Klin Wschr 1947; 59:531-534.
47. Ascher-Svanum H., Stensland MD, Kinon B J, Tollefson G D: Weight Gain and Improvement in Psychopathology During Treatment of Schizophrenia with Antipsychotics and with Placebo [abstract]. Biol Psychiatry 200455:27S.
48. Strassing M, Brar JS, Ganguli R: Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizoph Res 2003, 62:73-76.
49. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001, 62:92-100.
50. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC: Prevalence, Trends, and Factors Associated With Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients, 1998-2000. J Clin Psychiatry 2004; 65:1377- 1388.
51. Leslie DL, Rosenheck RA: From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry 2002; 159:1534-1540.
52. Awad AG, Voruganti LN: Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scale. Schizophr Res 2004; 70:63-67.